Randomised controlled trial

Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial

LancetPublished

  • Randomised controlled trial
  • open-label
  • 25 centres in the Netherlands

Authors' conclusion

Haemodynamic monitoring substantially improved quality of life and reduced heart failure hospitalisations in patients with moderate-to-severe heart failure treated according to contemporary guidelines.

Study context

Population
Chronic HF, NYHA class III, previous HF hospitalisation, irrespective of EF
Participants
348 participants
Comparison
Haemodynamic monitoring vs standard care
  • CardioMEMS-HFn = 176
  • Standard caren = 172reference
Primary endpoint
Mean difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score
Follow-up
12 months

Primary result

Change in KCCQ overall summary score

Difference in mean change

7.13

95% CI 1.51–12.75

P = 0.013

By group

CardioMEMS-HF

+7.05

mean change

Standard care

−0.08

mean change

CardioMEMS-HF vs Standard care
difference in mean change 7.13 (95% CI 1.51–12.75); P = 0.013

As reported in the abstract

Further findings

OutcomeOR (95% CI)P value
KCCQ responder analysis: improvement ≥5 points · 12 months1.69 (1.01–2.83)P = 0.046
KCCQ responder analysis: deterioration ≥5 points · 12 months0.45 (0.26–0.77)P = 0.0035

Safety

OutcomeCardioMEMS-HFStandard care
Freedom from device- or system-related complications and from sensor failure
Freedom from device/system-related complications97.7%Not reported in the abstract
Freedom from sensor failure98.8%Not reported in the abstract

Original publication

Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial. Lancet. Published 20 May 2023. doi:10.1016/s0140-6736(23)00923-6

Summarised from the published abstract; every number is checked against it